title: Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance.
abstract: Multidrug resistance (MDR) is a major cause of chemotherapy failure in the clinic. Drugs that were once effective against naïve disease subsequently prove ineffective against recurrent disease, which often exhibits an MDR phenotype. MDR can be attributed to many factors; often dominating among these is the ability of a cell to suppress or block drug entry through upregulation of membrane-bound drug efflux pumps. Efflux pumps exhibit polyspecificity, recognizing and exporting many different types of drugs, especially those whose lipophilic nature contributes to residence in the membrane. We have developed a general strategy to overcome efflux-based resistance. This strategy involves conjugating a known drug that succumbs to efflux-mediated resistance to a cell-penetrating molecular transporter, specifically, the cell-penetrating peptide (CPP), d-octaarginine. The resultant conjugates are discrete single entities (not particle mixtures) and highly water-soluble. They rapidly enter cells, are not substrates for efflux pumps, and release the free drug only after cellular entry at a rate controlled by linker design and favored by target cell chemistry. This general strategy can be applied to many classes of drugs and allows for an exceptionally rapid advance to clinical testing, especially of drugs that succumb to resistance. The efficacy of this strategy has been successfully demonstrated with Taxol in cellular and animal models of resistant cancer and with ex vivo samples from patients with ovarian cancer. Next generation efforts in this area will involve the extension of this strategy to other chemotherapeutics and other MDR-susceptible diseases.
authors.affiliation: Departments of Chemistry and Chemical and Systems Biology, Stanford University , Stanford, California 94305, United States.
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Vargas
authors.forename: Erika Geihe
authors.initials: EG
authors.lastname: Stanzl
authors.forename: Nelson N H
authors.initials: NN
authors.lastname: Teng
authors.forename: Paul A
authors.initials: PA
authors.lastname: Wender
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000737:chemistry; D000818:Animals; D001692:Biological Transport; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism; D004195:Disease Models, Animal; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D019791:Guanidine / Q000737:chemistry*; D006801:Humans; D051379:Mice; D009842:Oligopeptides / Q000737:chemistry; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage; D010455:Peptides / Q000737:chemistry; D021381:Protein Transport; D034622:RNA Interference; D012995:Solubility; D014867:Water / Q000737:chemistry
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D009842:Oligopeptides; D010455:Peptides; C448619:octaarginine; D014867:Water; D019791:Guanidine; D017239:Paclitaxel